Through the screening of numerous NSCLC PDX models, a novel anaplastic lymphoma kinase (ALK) rearrangement mutation, huntingtin interacting protein 1 (HIP1)-ALK fusion gene, was found to be sensitive to crizotinib (Fang et al., 2014). The gene discussed is ALK; the disease is non-small cell lung carcinoma.